Therapeutic results of laryngeal preservation: a retrospective study
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16273Keywords:
chemotherapy, concurrent chemoradiotherapy, laryngeal cancer., laryngeal preservation, radiotherapyAbstract
Summary. Aim: The objective of this study is to report the therapeutic results of the preservation strategy in locally advanced laryngeal cancers. Patients and Methods: Between January 2008 and December 2015, 24 patients with locoregional advanced non-metastatic laryngeal cancer (T2–4/N0–2) were collected retrospectively. Different therapeutic sequences were used: either induction chemotherapy followed by concurrent chemoradiotherapy or induction chemotherapy followed by radiotherapy or concurrent chemoradiotherapy or radiotherapy alone. Results: The objective response rate was 85.7%. Overall survival rates at 1 year, 3 years and 5 years were 91.3%, 80.2% and 53.5%, respectively. Administration of induction chemotherapy did not improve overall survival. The 1-year overall survival was 83.3% in the induction chemotherapy group vs 94.1% for those who did not received induction chemotherapy (p = 0.7). Conclusion: Our study showed the feasibility of this preservation strategy in clinical practice, with acceptable term toxicity.
References
Weir NF. Theodore Billroth: The first laryngectomy for cancer. J Laryngol Amp Otol 1973; 87: 1162–70.
Wolf GT, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685–90.
Jones TM, De M, Foran B, et al. Laryngeal cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol 2016; 130: S75–82.
Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091–8.
Forastiere AA, Ismaila N, Lewin JS, et al. Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2018 ; 36: 1143–69.
Lorch JH, Goloubeva O, Haddad RI, et al. Long term results of TAX324, a randomized phase III trial of sequential therapy with TPF versus PF in locally advanced squamous cell cancer of the head and neck. Lancet Oncol 2011; 12: 1539.
Argiris A , Lefebvre JL. Laryngeal preservation strategies in locally advanced laryngeal and hypopharyngeal cancers. Front Oncol 2019; 9: 419.
Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013; 31: 845–52.
Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013; 31: 853–9.
Janssens GO, Rademakers SE, Terhaard CH, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 2012; 30: 1777–83.
Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101: 498–506.
Posner MR, Norris CM, Wirth LJ, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol 2009; 20: 921–7.
Dietz A, Rudat V, Dreyhaupt J, et al. Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol 2009; 266: 1291–300.
Rudat V, Eckel H, Volling P, et al. Long-term results of a prospective multicenter phase II study to preserve the larynx function using concomitant boost radiochemotherapy with Carboplatin. Radiother Oncol 2008; 89: 33–7.
Divi V, Worden FP, Prince ME, et al. Chemotherapy alone for organ preservation in advanced laryngeal cancer. Head Neck 2010; 32: 1040–7.
Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890–9.
Janoray G, Pointreau Y, Garaud P, et al. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, ± docetaxel for larynx preservation. J Natl Cancer Inst 2016; 108: djv368.
Nguyen-Tan PF, Le QT, Quivey JM, et al. Treatment results and prognostic factors of advanced T3-4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys 2001; 50: 1172–80.
León X, Valero C, Rovira C, et al. Relationship between response to induction chemotherapy and disease control in patients with advanced laryngeal carcinoma included in an organ preservation protocol. Eur Arch Otorhinolaryngol 2017; 274: 2581–7.
Gorphe P, Matias M, Blanchard P, et al. Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy. The Laryngoscope 2017; 127: 1791–6.
Suzuki G, Yamazaki H, Ogo E, et al. Predisposing factors for larynx preservation strategies with non-surgical multimodality treatment for locally advanced (T3-4) larynx, hypopharynx and cervical esophageal disease. Anticancer Res 2014; 34: 5205–10.
Graff P, Lapeyre M, Desandes E, et al. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67: 1309–17.
Toledano I, Graff P, Serre A, et al. Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03. Radiother Oncol 2012; 103: 57–62.
Huang W-Y, Jen Y-M, Chen C-M, et al. Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer. Radiat Oncol Lond Engl 2010; 5: 37.
Mesía R, Garcia-Saenz JA, Lozano A, et al. Could the addition of cetuximab to conventional radiation therapy improve organ preservation in those patients with locally advanced larynx cancer who respond to induction chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study. Int J Radiat Oncol Biol Phys 2017; 97: 473–80.
Bonner J, Giralt J, Harari P, et al. Cetuximab and radiotherapy in laryngeal preservation for cancers of the larynx and hypopharynx. JAMA Otolaryngol Head Neck Surg 2016; 142: 842–9.
Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014; 32: 2940–50.
Peddi P, Shi R, Nair B, et al. Cisplatin, cetuximab, and radiation in locally advanced head and neck squamous cell cancer: a retrospective review. Clin Med Insights Oncol 2015; 9: 1–7.
Riaz N, Sherman E, Koutcher L, et al. Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. Am J Clin Oncol 2016; 39: 27–31.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
